- Bank of America Corp DE increased its holdings in Dyne Therapeutics, Inc. by 63.5% in the first quarter, owning 1,443,313 shares valued at $26,167,000.
- Several major institutional investors and hedge funds, including T. Rowe Price and Vanguard Group, also adjusted their stakes in the company during recent reporting periods.
- Dyne Therapeutics features a market capitalization of $4.80 billion and maintains a consensus analyst rating of Moderate Buy with an average target price of $34.42.